Effects of phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA)-induced differentiation and Bcl-2 overexpression on etoposide, lonidamine, and arsenic trioxide–induced apoptosis in U937 and HL60 human leukemic cells
| . | U937 . | U-TPA . | U-BCL2 . | HL60 . | HL-TPA . | HL-BCL2 . |
|---|---|---|---|---|---|---|
| Control | 2.8 ± 1.6 | 1.0 ± 0.6 | 0.8 ± 0.7 | 0.8 ± 0.7 | 1.3 ± 1.2 | 0.3 ± 0.7 |
| VP16 | ||||||
| 6 h | 71.7 ± 6.7 | 4.3 ± 2.1 | — | 46.3 ± 1.2 | 2.3 ± 2.6 | — |
| 24 h | 94.0 ± 1.6 | 22.3 ± 3.1 | — | 98.7 ± 1.2 | 9.5 ± 0.9 | — |
| LND | ||||||
| 24 h | 39.3 ± 3.5 | 16.3 ± 3.3 | 2.8 ± 1.1 | 79.7 ± 4.1 | 25.2 ± 5.2 | 3.3 ± 1.2 |
| 48 h | 93.3 ± 2.7 | 81.3 ± 5.5 | 4.5 ± 1.4 | 98.7 ± 0.7 | 67.5 ± 5.4 | 13.2 ± 2.6 |
| As2O3 | ||||||
| 24 h | 12.7 ± 2.1 | 26.8 ± 5.8 | 2.3 ± 2.0 | 8.0 ± 1.6 | 20.3 ± 3.7 | 0.3 ± 0.5 |
| 48 h | 30.3 ± 2.5 | 79.5 ± 8.0 | 2.7 ± 0.5 | 13.0 ± 5.5 | 60.7 ± 10.5 | 0.6 ± 0.5 |
| . | U937 . | U-TPA . | U-BCL2 . | HL60 . | HL-TPA . | HL-BCL2 . |
|---|---|---|---|---|---|---|
| Control | 2.8 ± 1.6 | 1.0 ± 0.6 | 0.8 ± 0.7 | 0.8 ± 0.7 | 1.3 ± 1.2 | 0.3 ± 0.7 |
| VP16 | ||||||
| 6 h | 71.7 ± 6.7 | 4.3 ± 2.1 | — | 46.3 ± 1.2 | 2.3 ± 2.6 | — |
| 24 h | 94.0 ± 1.6 | 22.3 ± 3.1 | — | 98.7 ± 1.2 | 9.5 ± 0.9 | — |
| LND | ||||||
| 24 h | 39.3 ± 3.5 | 16.3 ± 3.3 | 2.8 ± 1.1 | 79.7 ± 4.1 | 25.2 ± 5.2 | 3.3 ± 1.2 |
| 48 h | 93.3 ± 2.7 | 81.3 ± 5.5 | 4.5 ± 1.4 | 98.7 ± 0.7 | 67.5 ± 5.4 | 13.2 ± 2.6 |
| As2O3 | ||||||
| 24 h | 12.7 ± 2.1 | 26.8 ± 5.8 | 2.3 ± 2.0 | 8.0 ± 1.6 | 20.3 ± 3.7 | 0.3 ± 0.5 |
| 48 h | 30.3 ± 2.5 | 79.5 ± 8.0 | 2.7 ± 0.5 | 13.0 ± 5.5 | 60.7 ± 10.5 | 0.6 ± 0.5 |
Undifferentiated (U937, HL60), TPA-differentiated (U-TPA, HL-TPA), and Bcl-2 overexpressing (U-BCL2, HL-BCL2) U937 and HL60 cells were left untreated (control) or treated for indicated times with 50 μM etoposide (VP16), 200 μM lonidamine (LND), or 4 μM arsenic trioxide (As2O3). Results are expressed as percentages of apoptotic cells (mean ± SD of triplicate determinations).